600566.SH
济川药业
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 24.40
+0.04%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.9B | 6.2B | 8.0B | 9.7B | 9.0B |
| Cost of Revenue | 1.2B | 1.3B | 1.7B | 1.8B | 1.5B |
| Gross Profit | 4.7B | 4.9B | 6.4B | 7.9B | 7.5B |
| Operating Expenses | |||||
| R&D Expense | 391.0M | 385.1M | 444.8M | 464.4M | 553.3M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 461.8M | 448.0M | 432.7M | 372.8M | 364.2M |
| Selling & Marketing Expense | 2.0B | 2.1B | 3.0B | 4.0B | 4.1B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 2.9B | 3.0B | 3.7B | 4.7B | 5.1B |
| Cost and Expenses | 4.0B | 4.3B | 5.4B | 6.5B | 6.6B |
| Operating Income (EBIT) | 2.1B | 2.2B | 2.9B | 3.3B | 2.4B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 2.1B | 2.2B | 3.0B | 3.3B | 2.5B |
| Income Tax Expense | 385.7M | 384.0M | 441.5M | 470.0M | 336.2M |
| Bottom Line | |||||
| Net Income | 1.7B | 1.8B | 2.5B | 2.8B | 2.2B |
| Earnings from Cont. Ops | 1.7B | 1.8B | 2.5B | 2.8B | 2.2B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.7B | 1.8B | 2.5B | 2.8B | 2.2B |
| Per Share | |||||
| Basic EPS | CN¥1.89 | CN¥1.93 | CN¥2.76 | CN¥3.08 | CN¥2.44 |
| Diluted EPS | CN¥1.89 | CN¥1.93 | CN¥2.76 | CN¥3.08 | CN¥2.39 |
| Revenue Per Share | CN¥6.49 | CN¥6.75 | CN¥8.74 | CN¥10.53 | CN¥10.11 |
| Shares | |||||
| Basic Shares Outstanding | 909.4M | 921.2M | 917.2M | 916.5M | 889.7M |
| Diluted Shares Outstanding | 909.4M | 921.2M | 917.2M | 916.5M | 889.7M |
| Profitability Metrics | |||||
| EBITDA | — | 2.5B | 3.2B | 3.6B | 2.7B |
| D&A | — | 310.5M | 307.9M | 303.2M | 316.6M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026